Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-06-12
2007-06-12
Kifle, Bruck (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C540S521000
Reexamination Certificate
active
10500071
ABSTRACT:
Disclosed are 2-(1-isopropoxycarbonyloxy-2-methylpropyl)-7,8-dimethoxy-4(5H), 10-dioxo-2H-1,2,3-triazolo[4,5-c][1]benzazepine, which has been rendered amorphous and possesses improved absorption and dissoluvability, and a pharmaceutical composition comprising the same. Also disclosed are processes for producing 2-(1-isopropoxycarbonyloxy-2-methylpropyl)-7,8-dimethoxy-4(5H), 10-dioxo-2H-1,2,3-triazolo[4,5-c][1]benzazepine, which has been rendered amorphous, and a pharmaceutical composition comprising the same.
REFERENCES:
patent: 6372735 (2002-04-01), Ohtsuka et al.
patent: 99/16770 (1999-04-01), None
Hancock et al. (Pharmaceutical Research, vol. 17, No. 4, 2000).
Ishikura Toyoaki
Ishiwata Mayumi
Ishizawa Takayuki
Suemune Kenji
Udagawa Chikako
Heller Ehrman LLP
Kifle Bruck
Meiji Seika Kaisha Ltd.
LandOfFree
Amorphous substance of tricyclic triazolobenzazepine derivative does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Amorphous substance of tricyclic triazolobenzazepine derivative, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Amorphous substance of tricyclic triazolobenzazepine derivative will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3816152